The role and efficacy of serpatinib

Selpercatinib (Selpercatinib) is a revolutionary drug that plays an important role in anti-cancer treatment. As a highly selective and potent RET kinase inhibitor, it exhibits significant therapeutic effects on RET fusion-positive tumors through a specific mechanism of action.

The main effect of serpatinib is to inhibitRET kinase activity. The RET gene is a proto-oncogene, which under normal circumstances is involved in regulating cell growth and differentiation. However, when the RET gene is fused or mutated, it can lead to abnormal growth and spread of tumor cells. Serpatinib inhibits the proliferation of tumor cells by specifically binding to RET kinase and blocking its signaling pathway.

Selpatinib can bind to the ATP binding site ofRET kinase, preventing the binding of ATP to the kinase, thereby inhibiting the activity of the kinase. This inhibitory effect can block the signaling pathways downstream of RET kinase, such as PI3K/AKT, RAS/RAF/MEK/ERK, etc., thereby inhibiting the growth, division and invasion of tumor cells.

In addition, serpatinib can also induce tumor cell apoptosis. By activating apoptosis-related pathways, it promotes tumor cell death and further reduces tumor burden. This apoptosis induction contributes to enhancing the antitumor effect of serpatinib.

Serpatinib, as a targeted therapy, has shown significant efficacy in the treatment ofRET fusion-positive tumors. Currently, the drug is mainly used to treat non-small cell lung cancer (NSCLC) and thyroid cancer, two cancers in which the incidence of RET gene fusion is relatively high.

In the treatment of non-small cell lung cancer, serpatinib has a significant effect on RET fusion-positive patients. Clinical trial results show that among patients treated with serpatinib, a higher proportion of patients had tumor shrinkage or stabilization. Compared with traditional chemotherapy drugs, serpatinib can inhibit the progression of lung cancer more effectively, prolong patients' survival and improve their quality of life.

Especially for patients who have failed multiple lines of treatment, serpatinib can still demonstrate durable disease control effects. This discovery provides new treatment options for patients with non-small cell lung cancer, especially those who are insensitive or resistant to traditional chemotherapy drugs.

In the treatment of thyroid cancer, serpatinib has also shown impressive efficacy. For patients with RET fusion-positive thyroid cancer, after treatment with serpatinib, most patients' tumors have shrunk or stabilized, and some patients have even achieved complete tumor disappearance.

This finding opens up new treatment opportunities for thyroid cancer patients, especially those who are insensitive to or have developed resistance to traditional treatments. The emergence of serpatinib undoubtedly brings new hope to these patients.

In addition to the above two cancer types, serpatinib has also shown therapeutic effects on otherRET-driven cancers such as medullary thyroid cancer in clinical trials. With further research, serpatinib is expected to be used in the treatment of more types of tumors.

References:

https://www.ncbi.nlm.nih.gov/books/NBK601729/